Tag | Content |
---|---|
UniProt Accession | CTND1_HUMAN; O60716; |
Entrez ID | 1500 |
GenBank Protein ID | NM_001085458.1; NM_001085459.1; NM_001085460.1; NM_001085461.1; NM_001085462.1; NM_001085463.1; NM_001085464.1; NM_001085465.1; NM_001085466.1; NM_001085467.1; NM_001085468.1; NM_001085469.1; NM_001206883.1; NM_001206884.1; NM_001206885.1; NM_001206886.1; NM_001206887.1; NM_001206888.1; NM_001206889.1; NM_001206890.1; NM_001206891.1; NM_001331.2; |
GenBank Nucleotide ID | NP_001078927.1; NP_001078928.1; NP_001078929.1; NP_001078930.1; NP_001078931.1; NP_001078932.1; NP_001078933.1; NP_001078934.1; NP_001078935.1; NP_001078936.1; NP_001078937.1; NP_001078938.1; NP_001193812.1; NP_001193813.1; NP_001193814.1; NP_001193815.1; NP_001193816.1; NP_001193817.1; NP_001193818.1; NP_001193819.1; NP_001193820.1; NP_001322.1; |
Protein Name | Catenin delta-1 (Cadherin-associated Src substrate) (CAS) (p120 catenin) (p120(ctn)) (p120(cas)) |
Gene Name | CTNND1; KIAA0384 |
Organism | Homo sapiens |
NCBI Taxa ID | 9606 |
Functional Description | Binds to and inhibits the transcriptional repressor ZBTB33, which may lead to activation of target genes of the Wnt signaling pathway (By similarity). Associates with and regulates the cell adhesion properties of both C-, E- and N-cadherins, being critical for their surface stability. Implicated both in cell transformation by SRC and in ligand-induced receptor signaling through the EGF, PDGF, CSF-1 and ERBB2 receptors. Promotes GLIS2 C-terminal cleavage. |
Sequence (Fasta) | MDDSEVESTA SILASVKEQE AQFEKLTRAL EEERRHVSAQ LERVRVSPQD ANPLMANGTL 60 TRRHQNGRFV GDADLERQKF SDLKLNGPQD HSHLLYSTIP RMQEPGQIVE TYTEEDPEGA 120 MSVVSVETSD DGTTRRTETT VKKVVKTVTT RTVQPVAMGP DGLPVDASSV SNNYIQTLGR 180 DFRKNGNGGP GPYVGQAGTA TLPRNFHYPP DGYSRHYEDG YPGGSDNYGS LSRVTRIEER 240 YRPSMEGYRA PSRQDVYGPQ PQVRVGGSSV DLHRFHPEPY GLEDDQRSMG YDDLDYGMMS 300 DYGTARRTGT PSDPRRRLRS YEDMIGEEVP SDQYYWAPLA QHERGSLASL DSLRKGGPPP 360 PNWRQPELPE VIAMLGFRLD AVKSNAAAYL QHLCYRNDKV KTDVRKLKGI PVLVGLLDHP 420 KKEVHLGACG ALKNISFGRD QDNKIAIKNC DGVPALVRLL RKARDMDLTE VITGTLWNLS 480 SHDSIKMEIV DHALHALTDE VIIPHSGWER EPNEDCKPRH IEWESVLTNT AGCLRNVSSE 540 RSEARRKLRE CDGLVDALIF IVQAEIGQKD SDSKLVENCV CLLRNLSYQV HREIPQAERY 600 QEAAPNVANN TGPHAASCFG AKKGKDEWFS RGKKPIEDPA NDTVDFPKRT SPARGYELLF 660 QPEVVRIYIS LLKESKTPAI LEASAGAIQN LCAGRWTYGR YIRSALRQEK ALSAIADLLT 720 NEHERVVKAA SGALRNLAVD ARNKELIGKH AIPNLVKNLP GGQQNSSWNF SEDTVISILN 780 TINEVIAENL EAAKKLRETQ GIEKLVLINK SGNRSEKEVR AAALVLQTIW GYKELRKPLE 840 KEGWKKSDFQ VNLNNASRSQ SSHSYDDSTL PLIDRNQKSD KKPDREEIQM SNMGSNTKSL 900 DNNYSTPNER GDHNRTLDRS GDLGDMEPLK GTTPLMQDEG QESLEEELDV LVLDDEGGQV 960 SYPSMQKI 969 |
|
Database | Annotation |
---|---|
Cancer Gene Census | large intestine carcinoma |
GWASdb (count: 2) | rs11570190; Schizophrenia; schizophrenia
rs10896644; Amyotrophic lateral sclerosis (sporadic); amyotrophic lateral sclerosis |
PTM | Modification Sites |
---|---|
Phosphorylation (count: 113) (view all) | 11 SEVESTASILASVKE dbPAF
112 PGQIVETYTEEDPEG dbPAF 122 EDPEGAMSVVSVETS dbPAF 125 EGAMSVVSVETSDDG dbPAF 129 SVVSVETSDDGTTRR dbPAF 133 VETSDDGTTRRTETT dbPAF |
Acetylation (count: 4) | 25 EQEAQFEKLTRALEE PLMD
355 ASLDSLRKGGPPPPN PLMD 433 LGACGALKNISFGRD PLMD 574 GQKDSDSKLVENCVC PLMD |
Ubiquitination (count: 20) (view all) | 184 TLGRDFRKNGNGGPG PLMD
25 EQEAQFEKLTRALEE PLMD 355 ASLDSLRKGGPPPPN PLMD 408 KTDVRKLKGIPVLVG PLMD 517 REPNEDCKPRHIEWE PLMD 622 AASCFGAKKGKDEWF PLMD |
Sumoylation (count: 1) | 882 RNQKSDKKPDREEIQ PLMD |
Malonylation (count: 1) | 749 RNKELIGKHAIPNLV PLMD |
Network | Interaction | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
A | B | Source | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|